GlassScriptPhysician profile
Tiffany Kaul
NPI 1669050514
$1,706.04
in general payments reported to CMS, 2019-2025
28 companies · $551 in 2025
The $551 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $105 · 2024: $1,049 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.10 |
| Education | $179.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $340.13 | 2023-2025 | Fotivda |
| Sobi, INC | $146.62 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $145.90 | 2024-2025 | Imfinzi |
| Janssen Biotech, INC. | $134.68 | 2024-2025 | Darzalex, Rybrevant, Erleada |
| Glaxosmithkline, LLC. | $106.41 | 2024-2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $87.01 | 2024 | |
| Genentech USA, INC. | $86.93 | 2023-2025 | Venclexta |
| Abbvie INC. | $71.19 | 2025 | |
| Eisai INC. | $70.08 | 2024 | |
| Merck Sharp & Dohme LLC | $62.96 | 2025 | Lynparza, Keytruda, Keytruda Qlex |
| Servier Pharmaceuticals LLC | $39.02 | 2024 | |
| Dendreon Pharmaceuticals LLC | $35.00 | 2024 | Provenge |
| Celgene Corporation | $33.18 | 2024 | |
| Blueprint Medicines Corporation | $29.71 | 2024 | Ayvakit |
| Exelixis INC. | $29.21 | 2024 | Cabometyx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $28.83 | 2024 | |
| Daiichi Sankyo INC. | $25.30 | 2024 | Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $25.24 | 2024 | |
| Agios Pharmaceuticals, INC. | $24.04 | 2024 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $23.69 | 2025 | Ninlaro |
| Array Biopharma INC | $23.11 | 2025 | Mektovi, Xalkori, Braftovi |
| Incyte Corporation | $22.81 | 2024 | Jakafi |
| Alexion Pharmaceuticals, INC. | $20.61 | 2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.34 | 2025 | |
| Tempus Ai, INC | $19.69 | 2024 | |
| Lilly USA, LLC | $18.92 | 2024 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $18.61 | 2024 | Xermelo |
| Genmab U.S., INC. | $16.82 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.